SiBone (NASDAQ:SIBN) Stock: Insider Michael Pisetsky Sells 29,665 Shares

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 29,665 shares of the company’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $22.11, for a total value of $655,893.15. Following the completion of the sale, the senior vice president owned 164,444 shares of the company’s stock, valued at $3,635,856.84. This trade represents a 15.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

SiBone Trading Down 4.8%

SiBone stock traded down $1.01 during trading on Monday, reaching $20.22. 1,371,299 shares of the company were exchanged, compared to its average volume of 616,959. SiBone has a 52-week low of $11.48 and a 52-week high of $22.95. The company has a market capitalization of $896.74 million, a P/E ratio of -59.47 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The stock’s 50 day simple moving average is $19.41 and its two-hundred day simple moving average is $16.44.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. The business had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. On average, equities research analysts expect that SiBone will post -0.40 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SIBN has been the topic of a number of analyst reports. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. UBS Group boosted their target price on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Truist Financial increased their price target on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, TD Cowen raised their price target on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, SiBone currently has an average rating of “Moderate Buy” and an average target price of $24.50.

Institutional Investors Weigh In On SiBone

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Light Asset Management LLC grew its holdings in shares of SiBone by 51.8% during the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the period. Granahan Investment Management LLC increased its position in shares of SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after purchasing an additional 858,942 shares during the last quarter. Paradigm Capital Management Inc. NY increased its position in shares of SiBone by 113.3% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after purchasing an additional 598,300 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of SiBone by 41.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after purchasing an additional 182,465 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in SiBone by 101.6% in the 1st quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after buying an additional 238,219 shares during the period. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.